摘要
目的探讨表皮生长因子受体(epidermal growth factor receptor,EGFR)抑制剂易瑞沙联合奥沙利铂对人肝癌细胞株增殖和细胞凋亡的影响,为原发性肝癌分子靶向治疗和联合化疗提供临床依据。方法利用噻唑蓝(MTT)法测定奥沙利铂、易瑞沙对细胞增殖的抑制作用及两药联合时的细胞杀伤作用。重复试验3次,每次检测5孔细胞,将平均值作为最终结果,并用中效法则判定两药合用的效果。采用流式细胞仪测定易瑞沙单药应用于Hep-G2细胞,对细胞凋亡的影响。结果易瑞沙联合奥沙利铂增加化疗药对Hep-G2细胞的抑制作用,并呈时间剂量依赖性。易瑞沙单药作用于Hep-G2细胞,发生了细胞凋亡。结论易瑞沙与奥沙利铂的联合应用有望成为治疗肝癌的有效手段。
Objective To detect the effect of iressa(epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKI) combined with oxaliplatin on the proliferation and apoptosis of human HCCS Hep-G2 cells,and to provide the evidence for potential of combination of molecular target therapy with chemotherapy in the HCC clinical treatment.Methods Inhibitory effects of oxaliplatin used alone or combined with iressa on the proliferation of Hep-G2 cells were evaluated by MTT assay.The test was duplicated three times and...
出处
《胃肠病学和肝病学杂志》
CAS
2009年第11期1045-1047,共3页
Chinese Journal of Gastroenterology and Hepatology
关键词
表皮生长因子受体
肝癌细胞
奥沙利铂
Epidermal growth factor receptor
Hepatoma cells
Oxaliplatin
